Veru (VERU) news
Recent news
Veru - To advance oral sabizabulin for metastatic pancreatic cancer resistant to daraxonrasib
Veru Inc. has announced plans to advance the development of its oral microtubule agent, sabizabulin, for the treatment of metastatic pancreatic cancer that has developed resistance to daraxonrasib, a recently approved RAS inhibitor. This strategic move follows the FDA approval of daraxonrasib…
AInvest Wire · Sep 8, 2026Veru - Phase 2b Plateau trial interim analysis expected in Q1 2027
AInvest Wire · Aug 10, 2026Veru Q3 EPS USD -0.3
Veru Inc. (NASDAQ: VERU) is set to report its fiscal third-quarter 2026 earnings results on August 10, 2026, before the market opens. Analysts are projecting a loss of $0.32 per share for the quarter, with revenue expected to be $0 . This anticipated loss aligns with the company’s recent earnings…
AInvest Wire · Aug 10, 2026Veru reports fiscal 2026 third quarter financial results and Phase 2B Plateau clinical trial progress
AInvest Wire · Aug 10, 2026Veru - interim analysis results for Phase 2b Plateau trial expected in Q1 2027
AInvest Wire · Jul 27, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.